Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Classical hematology 2

Conditions

Myelodysplastic Syndromes 5Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Carcinoma, Squamous Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Malignant Neoplasmas 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Leukemia 1Esophageal Squamous Cell Carcinoma 1Epidermolysis Bullosa Dystrophica 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

fludarabine phosphate 52Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 42Busulfan 37Azacitidine 34Whole-Body Irradiation 31Mycophenolic Acid 29Cytarabine 28Cyclosporine 28Tacrolimus 27Methotrexate 25Filgrastim 21Decitabine 20Radiotherapy 19Antilymphocyte Serum 19Methylprednisolone 14Melphalan 13Etoposide 13fludarabine 10Cyclosporins 9Idarubicin 8Granulocyte Colony-Stimulating Factor 8Flow Cytometry 8sargramostim 7Psychiatric Rehabilitation 7Cord Blood Stem Cell Transplantation 7merphos 6aldesleukin 6Topotecan 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Chronic × ON 01910 × Clear all
NCT01926587 2021-06-16

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Traws Pharma, Inc.

Phase 1/2 Completed
45 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01241500 2020-06-30

ONTIME

Traws Pharma, Inc.

Phase 3 Completed
299 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01928537 2020-06-30

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Traws Pharma, Inc.

Phase 3 Completed
67 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡